BPL Medical Tech acquires South Korea’s Yozma BMtech

Launches advanced bone density systems in India & Dubai

FDA nod to LifeVac De Novo, paving for next-generation anti-choking device

The FDA classified LifeVac as a Class II medical device

Vertex Pharmaceuticals’ new kidney drug shows dramatic results in Phase 3 trial

The trial met its primary endpoint, with patients receiving povetacicept achieving a 52.0% reduction in UPCR at Week 36

Alcon launches Hydrus Microstent in India to transform glaucoma care

The Hydrus Microstent stands out as the first and only MIGS device backed by five-year clinical outcomes

Roche reports Phase III persevERA breast cancer trial results

Giredestrant shows promise despite missing primary goal

Bristol Myers Squibb reports positive phase 3 results for oral multiple myeloma therapy

The interim results of the Phase 3 SUCCESSOR-2 study's safety profile aligned with expectations for both mezigdomide and the combination regimen

Frontage Laboratories expands China presence with Teddy Lab acquisition

Novo Nordisk strikes deal with Hims & Hers, expands access to Ozempic & Wegovy in US

Under the deal, Hims & Hers will offer patients access to FDA-approved versions of Ozempic and Wegovy at the same self-pay prices available through other telehealth platforms

FDA nod to Bristol Myers Squibb’s Sotyktu as new oral therapy for psoriatic arthritis

The FDA decision was based on results from the pivotal POETYK PsA-1 and POETYK PsA-2 Phase 3 trials

Relmada’s NDV-01 shows strong 12-month results in hard-to-treat bladder cancer

The study showed a 76% complete response (CR) rate at 12 months, rising to 95% at any time for high-risk NMIBC patients